<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Harvard Law School Forum on Corporate Governance</title>
	<atom:link href="https://corpgov.law.harvard.edu/contributor/emil-buchman/feed/" rel="self" type="application/rss+xml" />
	<link>https://corpgov.law.harvard.edu</link>
	<description>The leading online blog in the fields of corporate governance and financial regulation.</description>
	<lastBuildDate>Tue, 15 Jun 2021 14:25:54 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.7.2</generator>
	<item>
		<title>COVID-19 as a Material Adverse Effect (MAC) Under M&#038;A and Financing Agreements</title>
		<link>https://corpgov.law.harvard.edu/2020/04/04/covid-19-as-a-material-adverse-effect-mac-under-ma-and-financing-agreements/</link>
		<comments>https://corpgov.law.harvard.edu/2020/04/04/covid-19-as-a-material-adverse-effect-mac-under-ma-and-financing-agreements/#respond</comments>
		<pubDate>Sat, 04 Apr 2020 13:43:37 +0000</pubDate>
<!-- 		<dc:creator><![CDATA[]]></dc:creator> -->
				<category><![CDATA[Mergers & Acquisitions]]></category>
		<category><![CDATA[Practitioner Publications]]></category>
		<category><![CDATA[Securities Litigation & Enforcement]]></category>
		<category><![CDATA[Acquisition agreements]]></category>
		<category><![CDATA[Adverse effects]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Merger litigation]]></category>
		<category><![CDATA[Mergers & acquisitions]]></category>
		<category><![CDATA[Securities litigation]]></category>
		<category><![CDATA[Shocks]]></category>
		<category><![CDATA[Systemic risk]]></category>

		<guid isPermaLink="false">https://corpgov.law.harvard.edu/?p=128006?d=20200404094337EDT</guid>
		<description><![CDATA[A critical legal issue that has arisen in recent days is whether the COVID-19 pandemic may constitute a “Material Adverse Change” (or “Material Adverse Effect”&#8211;both referred to here as a “MAC”) under existing agreements. We expect that every party to a merger agreement or financing agreement will be reviewing the agreement to determine whether any [&#8230;]]]></description>
				<content:encoded><![CDATA[<hgroup><em>Posted by Gail Weinstein, Warren de Wied, Steward Kagan, Fried, Frank, Harris, Shriver & Jacobson LLP, on Saturday, April 4, 2020 </em><div style="background:#F8F8F8;padding:10px;margin-top:5px;margin-bottom:10px"><strong>Editor's Note: </strong> <a class="external" href="http://www.friedfrank.com/index.cfm?pageID=42&amp;itemID=663" target="_blank" rel="nofollow noopener">Gail Weinstein</a> is senior counsel, and <a class="external" href="http://www.friedfrank.com/index.cfm?pageID=42&amp;itemID=1797&amp;more=1" target="_blank" rel="nofollow noopener">Warren S. de Wied</a> and <a href="https://www.friedfrank.com/index.cfm/sitefiles/news/index.cfm?pageID=42&amp;itemID=1572">Steward Kagan</a> are partners at Fried, Frank, Harris, Shriver &amp; Jacobson LLP. This post is based on a Fried Frank memorandum by Ms. Weinstein, Mr. de Wied, Mr. Kagan, <a href="https://www.friedfrank.com/index.cfm?pageID=42&amp;itemID=466">Christian Nahr</a>, <a href="https://www.friedfrank.com/index.cfm?pageID=42&amp;itemID=168">Emil Buchman</a>, and <a href="https://www.friedfrank.com/index.cfm?pageID=42&amp;itemID=741">Mark Hayek</a>.
</div></hgroup><p>A critical legal issue that has arisen in recent days is whether the COVID-19 pandemic may constitute a “Material Adverse Change” (or “Material Adverse Effect”&#8211;both referred to here as a “MAC”) under existing agreements. We expect that every party to a merger agreement or financing agreement will be reviewing the agreement to determine whether any party has a right to terminate the agreement or not perform certain obligations based on developments relating to the COVID-19 pandemic. Typically, the non-existence of a target company MAC is a condition to closing under a merger agreement; and the non-existence of a MAC on a borrower or its ability to perform under a credit facility is a condition to funds being drawn down. Even when a MAC (or other) provision does not clearly provide a right to terminate or not perform, the potential that a MAC has occurred may create leverage for a renegotiation of terms.</p>
<p> <a href="https://corpgov.law.harvard.edu/2020/04/04/covid-19-as-a-material-adverse-effect-mac-under-ma-and-financing-agreements/#more-128006" class="more-link"><span aria-label="Continue reading COVID-19 as a Material Adverse Effect (MAC) Under M&#038;A and Financing Agreements">(more&hellip;)</span></a></p>
]]></content:encoded>
			<wfw:commentRss>https://corpgov.law.harvard.edu/2020/04/04/covid-19-as-a-material-adverse-effect-mac-under-ma-and-financing-agreements/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
